- Home
- FTW vs ADCT Comparison
FTW vs ADCT Comparison
Compare FTW & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTW | ADCT |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.2M | 484.4M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FTW | ADCT |
|---|---|---|
| Price | $10.92 | $4.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 111.2K | ★ 741.8K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $9.50 | $1.20 |
| 52 Week High | $17.20 | $4.98 |
Technical Indicators
Market Signals| Indicator | FTW | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 64.25 |
| Support Level | $9.50 | $3.28 |
| Resistance Level | $13.83 | $4.77 |
| Average True Range (ATR) | 0.52 | 0.27 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 53.31 | 67.28 |
Price Performance
Historical ComparisonAbout FTW EQV Ventures Acquisition Corp. Class A Ordinary Shares
EQV Ventures Acquisition Corp is a blank check company.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).